We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$213M
Cap. Flow
-$89.6M
Cap. Flow %
-7.9%
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
32
Reduced
25
Closed
24

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$43.3M
2
TERN
Terns Pharmaceuticals
TERN
+$30M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$23.4M
4
TXG icon
10x Genomics
TXG
+$18.8M
5
ELVN icon
Enliven Therapeutics
ELVN
+$16.2M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$44.7M
2
UTHR icon
United Therapeutics
UTHR
+$31.3M
3
HCA icon
HCA Healthcare
HCA
+$17.2M
4
BIIB icon
Biogen
BIIB
+$15.7M
5
WGS icon
GeneDx Holdings
WGS
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
2 Consumer Staples 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
1
TG Therapeutics
TGTX
$8.58B
$64.9M 5.72%
3,645,562
+477,106
+15% +$7.61M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.23B
$60.5M 5.34%
7,548,000
+4,043,000
+115% +$43.3M
UTHR icon
3
United Therapeutics
UTHR
$26.3B
$45.1M 3.98%
141,499
-118,250
-46% -$31.3M
NRIX icon
4
Nurix Therapeutics
NRIX
$2.43B
$42.9M 3.78%
2,055,916
+940,916
+84% +$14.7M
FOCL
5
EDAP TMS S.A.
FOCL
$226M
$39.7M 3.5%
7,293,728
+66,375
+0.9% +$434K
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$33.7M 2.97%
+4,947,738
New +$30M
RVMD icon
7
Revolution Medicines
RVMD
$40.2B
$33.2M 2.93%
856,178
+127,478
+17% +$4.76M
SRDX
8
DELISTED
Surmodics
SRDX
$32.9M 2.9%
781,777
-19,043
-2% -$650K
ORGO icon
9
Organogenesis Holdings
ORGO
$308M
$32.3M 2.84%
11,518,954
+1,945,756
+20% +$5.22M
JSPR icon
10
Jasper Therapeutics
JSPR
$22.9M
$29M 2.55%
1,276,190
+89,094
+8% +$2.14M
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.41B
$24.4M 2.15%
694,069
+160,554
+30% +$6.36M
AXGN icon
12
Axogen
AXGN
$2.1B
$23.9M 2.11%
3,305,815
+200,000
+6% +$1.37M
KRYS icon
13
Krystal Biotech
KRYS
$9.88B
$23.1M 2.04%
126,000
+41,900
+50% +$7.03M
MRUS
14
DELISTED
Merus
MRUS
$22.3M 1.96%
376,321
+180,744
+92% +$8.75M
PEN icon
15
Penumbra
PEN
$12.5B
$22.2M 1.96%
123,450
+37,750
+44% +$7.54M
EPIX
16
DELISTED
ESSA Pharma
EPIX
$22.1M 1.95%
4,210,537
+620,979
+17% +$3.95M
PRAX icon
17
Praxis Precision Medicines
PRAX
$9.07B
$22M 1.94%
533,015
+495,747
+1,330% +$23.4M
CELC icon
18
Celcuity
CELC
$4.03B
$19.8M 1.75%
1,211,187
-520,151
-30% -$8.7M
NARI
19
DELISTED
Inari Medical, Inc. Common Stock
NARI
$19.7M 1.73%
408,373
+131,373
+47% +$5.82M
ONC
20
BeOne Medicines Ltd
ONC
$33.8B
$19.6M 1.73%
137,700
-10,400
-7% -$1.6M
CCCC icon
21
C4 Therapeutics
CCCC
$376M
$18.7M 1.65%
4,051,996
+1,593,000
+65% +$9.5M
CSTL icon
22
Castle Biosciences
CSTL
$749M
$18.6M 1.64%
853,628
+128,171
+18% +$2.86M
NPCE icon
23
Neuropace
NPCE
$505M
$18.4M 1.62%
2,433,168
– –
ELVN icon
24
Enliven Therapeutics
ELVN
$3.78B
$18M 1.59%
+769,263
New +$16.2M
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$36.3B
$17.4M 1.54%
+71,700
New +$11.3M
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Soleus Capital Management held 116 positions worth $1.13B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Soleus Capital Management withdrew a net $89.6M in Q2 2024, closing 24 positions and reducing 25 holdings. Its most notable exit was HCA Healthcare, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Terns Pharmaceuticals worth $33.7M.

  • Soleus Capital Management's largest Q2 2024 buy was Terns Pharmaceuticals: 4,947,738 shares worth $33.7M.
  • Soleus Capital Management added most to Iovance Biotherapeutics in Q2 2024, an estimated $43.3M increase.
  • Soleus Capital Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $44.7M.
  • Soleus Capital Management fully exited HCA Healthcare in Q2 2024, selling an estimated $17.2M.
  • Soleus Capital Management's ten largest holdings make up 37% of its $1.13B portfolio in Q2 2024.
  • Soleus Capital Management opened 25 new positions and closed 24 in Q2 2024.
  • Soleus Capital Management's portfolio value fell 16% quarter-over-quarter to $1.13B.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.